ObjectiveTo investigate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) in comprehensively treating neovascular glaucoma. MethodsThe clinical data of 60 patients (60 eyes) with neovascular glaucoma were retrospectively analyzed, of them, 30 patients received intravitreal injection with conbercept combined with compound trabeculectomy and panretinal photocoagulation were selected as the observation group, while the other 30 patients received compound trabeculectomy combined with panretinal photocoagulation, but without intravitreal injection with conbercept were included in the control group. The pre- and post-operative intraocular pressure, visual acuity changes, treatment success rate and complications were compared between the two groups. ResultsAt 3 days, 7 days, 1 month, 3 months after the operation, the intraocular pressure levels of the two groups were significantly lower than those before operation, and the observation group had a lower level as compared with the control group (all P＜0.05). There was no statistically significant difference in postoperative visual acuity improvement between the two groups (P＞0.05). The observation group yielded a higher treatment success rate, whereas a lower incidence of total complications as compared to the control group (all P＜0.05). ConclusionConbercept intravitreal injection combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma can effectively decrease intraocular pressure and protect residual visual acuity, and thus the efficacy is safe and reliable.

无